rilparencel PROACT is a Prokidney Corp. program in advanced CKD with type 2 diabetes. Its next catalyst is a Readout in Q2 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: Advanced CKD with type 2 diabetes. Sponsor: Prokidney Corp. (PROK). We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for rilparencel PROACT is a Readout in Q2 2027.
No FDA decision for rilparencel PROACT is in our archive yet.
In our records rilparencel PROACT is under review or in development for Advanced CKD with type 2 diabetes.
Prokidney Corp. (PROK).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.